BNP Paribas Financial Markets Purchases 497,457 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

BNP Paribas Financial Markets grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 15,449.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 500,677 shares of the company's stock after buying an additional 497,457 shares during the quarter. BNP Paribas Financial Markets' holdings in Takeda Pharmaceutical were worth $6,629,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. American Trust Investment Advisors LLC grew its stake in Takeda Pharmaceutical by 37.7% in the 4th quarter. American Trust Investment Advisors LLC now owns 45,645 shares of the company's stock valued at $604,000 after purchasing an additional 12,500 shares during the period. Jane Street Group LLC boosted its holdings in shares of Takeda Pharmaceutical by 109.0% in the 4th quarter. Jane Street Group LLC now owns 254,647 shares of the company's stock worth $3,372,000 after buying an additional 132,817 shares during the last quarter. Lido Advisors LLC bought a new position in Takeda Pharmaceutical during the fourth quarter valued at about $364,000. Northern Trust Corp grew its position in Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after buying an additional 238,161 shares during the period. Finally, Aquatic Capital Management LLC increased its holdings in Takeda Pharmaceutical by 52.0% during the fourth quarter. Aquatic Capital Management LLC now owns 180,927 shares of the company's stock worth $2,395,000 after buying an additional 61,927 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded up $0.11 during mid-day trading on Friday, hitting $14.11. The stock had a trading volume of 1,136,705 shares, compared to its average volume of 1,911,866. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The business has a fifty day moving average price of $14.78 and a 200-day moving average price of $14.00. The firm has a market cap of $44.88 billion, a P/E ratio of 35.26, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. On average, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.